MindMed is a leader in the biotech space. The company is hard at work developing psychedelic-derived therapies to improve the human condition. MindMed's 18-MC clinical trial centered on the testing of a non-hallucinogenic drug that is a proprietary derivative of ibogaine. Ibogaine has been analyzed and uses as a treatment modality for opioid addiction in the past. The industry's top scientists insist ibogaine has promise yet there are some concerns regarding whether it is completely safe for human use.